Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.

Research output: Contribution to journal › Article › peer-review

ASJC Scopus subject areas

@article{9bd57d1f5cfe4849961549a161f0a43e,

title = "Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.",

author = "Alexander Maxwell",

year = "2007",

month = sep,

doi = "10.1159/000106507",

language = "English",

volume = "107(1)",

pages = "c14--9--c19",

journal = "Nephron. Clinical practice",

issn = "1660-2110",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.

AU - Maxwell, Alexander

PY - 2007/9

Y1 - 2007/9

UR - http://www.scopus.com/inward/record.url?scp=34548455346&partnerID=8YFLogxK

U2 - 10.1159/000106507

DO - 10.1159/000106507

M3 - Article

C2 - 17664890

SN - 1660-2110

VL - 107(1)

SP - c14-9-c19

JO - Nephron. Clinical practice

JF - Nephron. Clinical practice

IS - 1

ER -